RHYTHM PHARMACEUTICALS INC (RYTM) — insider trading
Health Care · NASDAQ
RHYTHM PHARMACEUTICALS INC (RYTM) has 74 reported SEC Form 4 insider transactions in our data, including 22 open-market sales among the most recent 74 (latest 2026-09-14).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Option exercise / conversion (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Open-market sale | 2,300 | $105.19 | $241.9K | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Open-market sale | 1,817 | $104.55 | $190.0K | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Open-market sale | 8,698 | $103.43 | $899.6K | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Open-market sale | 30,746 | $102.35 | $3.15M | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Open-market sale | 6,439 | $101.75 | $655.1K | Form 4 |
| 2026-09-14 | Meeker David P | Director, Officer (President and CEO) | Option exercise / conversion | 50,000 | $6.05 | $302.5K | Form 4 |
| 2026-08-31 | Smith Hunter C | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 57,187 | — | $0 | Form 4 |
| 2026-08-31 | Smith Hunter C | Officer (Chief Financial Officer) | Open-market sale | 28,188 | $106.20 | $2.99M | Form 4 |
| 2026-08-31 | Smith Hunter C | Officer (Chief Financial Officer) | Open-market sale | 11,514 | $105.37 | $1.21M | Form 4 |
| 2026-08-31 | Smith Hunter C | Officer (Chief Financial Officer) | Open-market sale | 23,072 | $104.59 | $2.41M | Form 4 |
| 2026-08-31 | Smith Hunter C | Officer (Chief Financial Officer) | Option exercise / conversion | 57,187 | $25.79 | $1.47M | Form 4 |
| 2026-08-17 | Joshi Manher | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 25,000 | — | $0 | Form 4 |
| 2026-08-17 | Joshi Manher | Officer (Chief Medical Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-08-13 | Garfield Alastair | Officer (Chief Scientific Officer) | Open-market sale | 800 | $119.17 | $95.3K | Form 4 |
| 2026-08-13 | Garfield Alastair | Officer (Chief Scientific Officer) | Open-market sale | 3,400 | $118.28 | $402.2K | Form 4 |
| 2026-08-13 | Garfield Alastair | Officer (Chief Scientific Officer) | Open-market sale | 1,556 | $117.08 | $182.2K | Form 4 |
| 2026-08-13 | Garfield Alastair | Officer (Chief Scientific Officer) | Open-market sale | 2,007 | $116.11 | $233.0K | Form 4 |
| 2026-08-13 | Shulman Joseph | Officer (Chief Technical Officer) | Option exercise / conversion (derivative) | 2,024 | — | $0 | Form 4 |
| 2026-08-13 | Shulman Joseph | Officer (Chief Technical Officer) | Open-market sale | 5,079 | $119.75 | $608.2K | Form 4 |
| 2026-08-13 | Shulman Joseph | Officer (Chief Technical Officer) | Option exercise / conversion | 2,024 | $6.80 | $13.8K | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Officer (EVP, Head of North America) | Option exercise / conversion (derivative) | 21,601 | — | $0 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Officer (EVP, Head of North America) | Option exercise / conversion (derivative) | 35,000 | — | $0 | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Officer (EVP, Head of North America) | Open-market sale | 75,834 | $117.38 | $8.90M | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Officer (EVP, Head of North America) | Option exercise / conversion | 21,601 | $6.80 | $146.9K | Form 4 |
| 2026-08-13 | Lee Jennifer Kayden | Officer (EVP, Head of North America) | Option exercise / conversion | 35,000 | $24.29 | $850.1K | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Option exercise / conversion (derivative) | 46,625 | — | $0 | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 17,319 | $117.47 | $2.03M | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 18,208 | $116.49 | $2.12M | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 14,568 | $115.43 | $1.68M | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 3,605 | $114.70 | $413.5K | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 1,000 | $112.86 | $112.9K | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Open-market sale | 2,300 | $111.80 | $257.1K | Form 4 |
| 2026-08-12 | Mazabraud Yann | Officer (EVP, Head of International) | Option exercise / conversion | 46,625 | $6.80 | $317.1K | Form 4 |
| 2026-07-01 | Garfield Alastair | Officer (Chief Scientific Officer) | Option exercise / conversion (derivative) | 4,445 | — | $0 | Form 4 |
| 2026-07-01 | Garfield Alastair | Officer (Chief Scientific Officer) | Shares withheld for taxes / exercise cost | 2,150 | $110.41 | $237.4K | Form 4 |
| 2026-07-01 | Garfield Alastair | Officer (Chief Scientific Officer) | Option exercise / conversion | 4,445 | — | — | Form 4 |
| 2026-06-24 | GOOD JENNIFER L | Director | Grant / award / vesting (derivative) | 2,324 | — | $0 | Form 4 |
| 2026-06-24 | GOOD JENNIFER L | Director | Grant / award / vesting (derivative) | 3,691 | — | $0 | Form 4 |
| 2026-06-24 | Arbuckle Stuart A | Director | Grant / award / vesting (derivative) | 2,324 | — | $0 | Form 4 |
| 2026-06-24 | Arbuckle Stuart A | Director | Grant / award / vesting (derivative) | 3,691 | — | $0 | Form 4 |
| 2026-06-24 | TETRAULT LYNN A. | Director | Grant / award / vesting (derivative) | 2,324 | — | $0 | Form 4 |
| 2026-06-24 | TETRAULT LYNN A. | Director | Grant / award / vesting (derivative) | 3,691 | — | $0 | Form 4 |
| 2026-06-24 | MCGIRR DAVID W J | Director | Grant / award / vesting (derivative) | 2,324 | — | $0 | Form 4 |
| 2026-06-24 | MCGIRR DAVID W J | Director | Grant / award / vesting (derivative) | 3,691 | — | $0 | Form 4 |
| 2026-06-24 | JEAN CHRISTOPHE | Director | Grant / award / vesting (derivative) | 2,324 | — | $0 | Form 4 |
| 2026-06-24 | JEAN CHRISTOPHE | Director | Grant / award / vesting (derivative) | 3,691 | — | $0 | Form 4 |
| 2026-06-23 | GOOD JENNIFER L | Director | Option exercise / conversion (derivative) | 4,712 | — | $0 | Form 4 |
| 2026-06-23 | GOOD JENNIFER L | Director | Option exercise / conversion | 4,712 | — | — | Form 4 |
| 2026-06-23 | Arbuckle Stuart A | Director | Option exercise / conversion (derivative) | 4,712 | — | $0 | Form 4 |
| 2026-06-23 | Arbuckle Stuart A | Director | Option exercise / conversion | 4,712 | — | — | Form 4 |
| 2026-06-23 | TETRAULT LYNN A. | Director | Option exercise / conversion (derivative) | 4,712 | — | $0 | Form 4 |
| 2026-06-23 | TETRAULT LYNN A. | Director | Option exercise / conversion | 4,712 | — | — | Form 4 |
| 2026-06-23 | MCGIRR DAVID W J | Director | Option exercise / conversion (derivative) | 4,712 | — | $0 | Form 4 |
| 2026-06-23 | MCGIRR DAVID W J | Director | Option exercise / conversion | 4,712 | — | — | Form 4 |
| 2026-06-23 | JEAN CHRISTOPHE | Director | Option exercise / conversion (derivative) | 4,712 | — | $0 | Form 4 |
| 2026-06-23 | JEAN CHRISTOPHE | Director | Option exercise / conversion | 4,712 | — | — | Form 4 |
| 2026-06-22 | TETRAULT LYNN A. | Director | Option exercise / conversion (derivative) | 37,000 | — | $0 | Form 4 |
| 2026-06-22 | TETRAULT LYNN A. | Director | Open-market sale | 37,000 | $100.32 | $3.71M | Form 4 |
| 2026-06-22 | TETRAULT LYNN A. | Director | Option exercise / conversion | 37,000 | $28.27 | $1.05M | Form 4 |
| 2026-05-18 | Smith Hunter C | Officer (Chief Financial Officer) | Option exercise / conversion (derivative) | 3,000 | — | $0 | Form 4 |
| 2026-05-18 | Smith Hunter C | Officer (Chief Financial Officer) | Option exercise / conversion | 3,000 | $17.87 | $53.6K | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion (derivative) | 1,406 | — | $0 | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion (derivative) | 1,349 | — | $0 | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion (derivative) | 1,687 | — | $0 | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Open-market sale | 4,643 | $92.21 | $428.1K | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion | 1,406 | $17.97 | $25.3K | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion | 1,349 | $49.23 | $66.4K | Form 4 |
| 2026-05-15 | German Christopher Paul | Officer (Corporate Controller & CAO) | Option exercise / conversion | 1,687 | $56.69 | $95.6K | Form 4 |
| 2026-04-01 | Popovits Kimberly J | Director | Grant / award / vesting (derivative) | 10,257 | — | $0 | Form 4 |
| 2026-04-01 | Popovits Kimberly J | Director | Grant / award / vesting (derivative) | 6,808 | — | $0 | Form 4 |
| 2026-04-01 | Mazabraud Yann | Officer (EVP, Head of International) | Option exercise / conversion (derivative) | 2,500 | — | $0 | Form 4 |
| 2026-04-01 | Mazabraud Yann | Officer (EVP, Head of International) | Option exercise / conversion (derivative) | 10,375 | — | $0 | Form 4 |
| 2026-04-01 | Mazabraud Yann | Officer (EVP, Head of International) | Option exercise / conversion | 12,875 | — | — | Form 4 |
Ask the chat about RYTM's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: RHYTHM PHARMACEUTICALS INC (RYTM).
Last updated 2026-09-14 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.